A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit® in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change in hemoglobin

Safety Issue:

No

Principal Investigator

Naomi V. Dahl, Pharm.D.

Investigator Role:

Study Director

Investigator Affiliation:

Watson Laboratories, Inc.

Authority:

United States: Food and Drug Administration

Study ID:

FR01008

NCT ID:

NCT00224068

Start Date:

May 2002

Completion Date:

December 2003

Related Keywords:

• Anemia
• Iron deficiency
• Sodium ferric gluconate
• anemia
• cancer chemotherapy
• epoetin alfa
• Anemia/drug therapy
• Anemia, Iron-Deficiency/drug therapy/etiology
• Hematinics/administration & dosage/pharmacology
• Antineoplastic Agents/adverse effects
• Erythropoietin, Recombinant/therapeutic use/adverse effects
• Anemia